ALPMF: AI 评分 58/100 — AI 分析 (4月 2026)

Astellas Pharma Inc. is a global pharmaceutical company focused on developing and marketing innovative medicines across various therapeutic areas. The company's portfolio includes treatments for prostate cancer, hematologic malignancies, and overactive bladder, among others.

Key Facts: AI Score: 58/100 Sector: Healthcare

公司概况

概要：

Astellas Pharma Inc. is a global pharmaceutical company specializing in prescription pharmaceuticals across key therapeutic areas like oncology, urology, and immunology. With a focus on innovation and strategic collaborations, Astellas develops and commercializes drugs such as XTANDI and PADCEV, maintaining a significant presence in the competitive pharmaceutical landscape.

ALPMF是做什么的？

Founded in 1923 and headquartered in Tokyo, Japan, Astellas Pharma Inc. has evolved into a global pharmaceutical leader. The company engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas's product portfolio includes XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia; PADCEV, a treatment for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for overactive bladder; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, immunosuppressants used post-transplant. The company also offers treatments like mirabegron for neurogenic detrusor overactivity in pediatric patients, Vesicare for OAB treatment, Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, and Funguard/MYCAMINE, an antifungal agent. Astellas has established strategic collaborations with companies like Merck & Co., Inc., CytomX Therapeutics, Inc., and BANDAI NAMCO Entertainment Inc. to expand its research and development efforts. These collaborations enable Astellas to explore new therapeutic areas and technologies, reinforcing its commitment to addressing unmet medical needs.

ALPMF的投资论点是什么？

Astellas Pharma Inc. presents a compelling investment thesis based on its diverse product portfolio and strategic collaborations. With a P/E ratio of 12.95 and a profit margin of 15.7%, the company demonstrates financial stability. Key growth drivers include the continued expansion of XTANDI in prostate cancer treatment and the uptake of PADCEV in urothelial cancer. The company's dividend yield of 3.26% offers an attractive return for investors. However, potential risks include patent expirations and competition from biosimilars. Astellas's strategic research alliances, such as the one with Harvard University, position it for long-term innovation and growth.

ALPMF在哪个行业运营？

Astellas Pharma Inc. operates in the global pharmaceutical industry, characterized by intense competition, stringent regulatory requirements, and continuous innovation. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. Astellas competes with major pharmaceutical companies, including BMXXY (Bayer AG) and CHJTF (Chugai Pharmaceutical Co.), focusing on specialized therapeutic areas. The industry is witnessing a shift towards personalized medicine and targeted therapies, requiring companies to invest heavily in research and development.

Drug Manufacturers - General

Healthcare

ALPMF有哪些增长机遇？

Expansion of XTANDI: XTANDI, an androgen receptor signaling inhibitor for prostate cancer, presents a significant growth opportunity. The global prostate cancer market is projected to reach $12 billion by 2028. Astellas can capitalize on this by expanding XTANDI's indications and geographic reach. The company's ongoing clinical trials and marketing efforts will be crucial in driving future growth.
Uptake of PADCEV: PADCEV, a treatment for urothelial cancer, offers another growth avenue. The urothelial cancer market is expected to grow as the global population ages. Astellas can increase PADCEV's market share through strategic partnerships and clinical trial advancements. The company's focus on addressing unmet needs in cancer treatment positions it well for future expansion.
Strategic Collaborations: Astellas's strategic collaborations, such as the one with Harvard University, provide access to innovative technologies and therapeutic approaches. These collaborations can lead to the development of new drugs and therapies, driving long-term growth. The company's ability to identify and partner with leading research institutions will be critical in maintaining its competitive edge.
Geographic Expansion: Expanding into emerging markets represents a significant growth opportunity for Astellas. These markets offer high growth potential due to increasing healthcare spending and unmet medical needs. Astellas can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets. The company's focus on globalization will be essential in driving future revenue growth.
Development of Cell Therapies: The strategic collaboration and license agreement with Minovia Therapeutics Ltd. for cell therapy programs targeting mitochondrial dysfunction presents a novel growth opportunity. As cell therapies gain traction in treating various diseases, Astellas's investment in this area could yield significant returns. This collaboration allows Astellas to explore innovative treatment modalities and expand its therapeutic offerings.

Market capitalization of $29.34 billion reflects Astellas's significant presence in the pharmaceutical industry.
P/E ratio of 12.95 indicates a reasonable valuation compared to its earnings.
Gross margin of 77.7% demonstrates strong pricing power and efficient cost management.
Dividend yield of 3.26% provides an attractive income stream for investors.
Beta of 0.12 suggests low volatility compared to the broader market.

ALPMF提供哪些产品和服务？

Develops and commercializes prescription pharmaceuticals.
Focuses on therapeutic areas such as oncology, urology, and immunology.
Manufactures and markets drugs like XTANDI for prostate cancer.
Offers treatments for overactive bladder, including Betanis/Myrbetriq/BETMIGA.
Provides immunosuppressants like Prograf and Advagraf/Graceptor/ASTAGRAF for transplant patients.
Engages in strategic collaborations to expand research and development efforts.

ALPMF如何赚钱？

Develops and patents innovative pharmaceutical products.
Conducts clinical trials to demonstrate safety and efficacy.
Markets and sells prescription drugs through a global distribution network.
Collaborates with other companies and research institutions to expand its product pipeline.

Patients requiring prescription medications.
Hospitals and clinics.
Pharmacies.
Healthcare providers.

Patent protection for key drugs like XTANDI.
Strong brand reputation and established market presence.
Strategic collaborations with leading research institutions.
Specialized expertise in key therapeutic areas.

什么因素可能推动ALPMF股价上涨？

Ongoing: Continued expansion of XTANDI in prostate cancer treatment.
Ongoing: Uptake of PADCEV in urothelial cancer.
Upcoming: Results from ongoing clinical trials for new therapies.
Ongoing: Strategic collaborations with research institutions.
Ongoing: Geographic expansion into emerging markets.

ALPMF的主要风险是什么？

Potential: Patent expirations on key drugs.
Potential: Competition from generic and biosimilar drugs.
Potential: Regulatory setbacks and delays in drug approvals.
Potential: Product liability claims and litigation risks.
Ongoing: Economic downturns affecting healthcare spending.

ALPMF的核心优势是什么？

Diverse product portfolio across multiple therapeutic areas.
Strong research and development capabilities.
Strategic collaborations with leading research institutions.
Global presence and established distribution network.

ALPMF的劣势是什么？

Reliance on key products like XTANDI.
Exposure to patent expirations and generic competition.
Dependence on regulatory approvals for new drugs.
Limited presence in emerging markets compared to some competitors.

ALPMF有哪些机遇？

Expansion into new therapeutic areas, such as cell therapies.
Growth in emerging markets with increasing healthcare spending.
Development of personalized medicine and targeted therapies.
Strategic acquisitions to expand product portfolio and market reach.

ALPMF面临哪些威胁？

Increasing competition from generic and biosimilar drugs.
Stringent regulatory requirements and potential delays in drug approvals.
Economic downturns affecting healthcare spending.
Product liability claims and litigation risks.

ALPMF的竞争对手是谁？

Bayer AG — Diversified pharmaceutical and life sciences company. — (BMXXY)
Chugai Pharmaceutical Co. — Japanese pharmaceutical company focused on biotechnology. — (CHJTF)
CSPC Pharmaceutical Group Ltd. — Chinese pharmaceutical company with a broad product portfolio. — (CSPCY)
Fresenius Medical Care AG & Co. — Provides dialysis products and services. — (FMCQF)
Grifols SA — Global healthcare company producing plasma-derived therapies. — (GIKLY)

Key Metrics

MoonshotScore: 58/100

Company Profile

CEO: Naoki Okamura
Headquarters: Tokyo, JP
Employees: 14,754
Founded: 2010

AI Insight

AI analysis pending for ALPMF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Astellas Pharma Inc. do?

Astellas Pharma Inc. is a global pharmaceutical company that develops, manufactures, and markets prescription drugs across various therapeutic areas, including oncology, urology, and immunology. The company's key products include XTANDI for prostate cancer, PADCEV for urothelial cancer, and Betanis/Myrbetriq/BETMIGA for overactive bladder. Astellas focuses on innovation and strategic collaborations to address unmet medical needs and improve patient outcomes. The company operates globally, with a significant presence in Japan, the United States, and Europe.

What do analysts say about ALPMF stock?

Analyst consensus on ALPMF stock is pending AI analysis. Key valuation metrics include a P/E ratio of 12.95 and a dividend yield of 3.26%. Growth considerations include the continued expansion of XTANDI and PADCEV, as well as strategic collaborations and geographic expansion. Investors should conduct their own research and consider their individual risk tolerance before making any investment decisions. No buy or sell recommendations are made here.

What are the main risks for ALPMF?

The main risks for Astellas Pharma Inc. include patent expirations on key drugs, competition from generic and biosimilar drugs, regulatory setbacks and delays in drug approvals, product liability claims, and economic downturns affecting healthcare spending. The company's reliance on key products like XTANDI exposes it to potential revenue declines if generic versions become available. Regulatory risks include the potential for delays or rejections of new drug applications. Economic risks include the impact of economic downturns on healthcare spending and demand for pharmaceutical products.

How does Astellas Pharma Inc. manage patent expiration risks?

Astellas Pharma Inc. manages patent expiration risks through a combination of strategies, including developing new formulations and indications for existing drugs, pursuing patent extensions, and investing in research and development to create new innovative products. The company also focuses on lifecycle management strategies to extend the market exclusivity of its key products. By diversifying its product portfolio and investing in innovation, Astellas aims to mitigate the impact of patent expirations on its revenue and profitability.

What are the key growth opportunities for ALPMF in healthcare?

Key growth opportunities for Astellas Pharma Inc. in healthcare include expanding into new therapeutic areas, such as cell therapies, and geographic markets, particularly emerging economies. The company's strategic collaboration with Minovia Therapeutics Ltd. for cell therapy programs targeting mitochondrial dysfunction presents a novel growth opportunity. Additionally, Astellas can capitalize on the increasing healthcare spending in emerging markets by expanding its presence and product offerings in these regions. The company's focus on personalized medicine and targeted therapies also positions it well for future growth.